trending Market Intelligence /marketintelligence/en/news-insights/trending/y25XrrMe1yC8nNQa7btIaA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cipla posts fiscal Q4 loss as provisions bite

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cipla posts fiscal Q4 loss as provisions bite

Cipla Ltd. reported a loss per share of 77 Indian paise for the fiscal fourth quarter ended March 31, compared to the year-ago loss per share of 1.15 rupees.

The S&P Capital IQ consensus normalized EPS estimate for the fourth quarter is 4.45 rupees.

The Indian pharmaceutical company posted a net loss of 617.9 million rupees during the period, compared to a loss of 928.3 million rupees a year earlier.

Cipla said its fiscal fourth-quarter results included provision in relation to certain assets in unit Cipla Biotec Pvt. Ltd. amounting to 560.0 million rupees. The results also included an impact of the noncash impairment of certain product-related intangible assets of the company's U.S. generics business amounting to 2.14 billion rupees.

Net sales totaled 34.87 billion rupees, up from 32.53 billion rupees in the year-ago period. After-tax loss amounted to 608.6 million rupees, compared to 813.2 million rupees in the fourth quarter of fiscal 2016.

For the fiscal year ended March 31, the company reported a year-over-year decline in net profit to 10.064 trillion rupees, or 12.5 rupees per share, from 13.60 trillion rupees, or 16.89 rupees per share.

The S&P Capital IQ consensus normalized EPS estimate for 2017 is 17.95 rupees.

Cipla's board recommended a dividend payment of 2 rupees per equity share for the 2017 fiscal year.

As of May 25, US$1 was equivalent to 64.56 Indian rupees.